Francesco and colleagues presented evidence for the downregulation of CCDC6 protein enhancing tumor aggressiveness and reducing sensitivity to DNA damaging agents, such as cisplatinum, in patients with non-small cell lung cancer (NSCLC). The gene discussed is CCDC6; the disease is neoplasm.